State of New Jersey Common Pension Fund D Acquires Shares of 36,833 Arcutis Biotherapeutics, Inc. $ARQT

Posted by Brenda Bartman on May 12th, 2026

State of New Jersey Common Pension Fund D bought a new stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 36,833 shares of the company’s stock, valued at approximately $1,070,000.

A number of other hedge funds also recently made changes to their positions in the business. Jennison Associates LLC grew its position in Arcutis Biotherapeutics by 10.3% during the third quarter. Jennison Associates LLC now owns 12,254,119 shares of the company’s stock valued at $230,990,000 after buying an additional 1,144,714 shares during the period. Voloridge Investment Management LLC bought a new stake in Arcutis Biotherapeutics in the third quarter worth about $15,711,000. Bank of America Corp DE raised its position in Arcutis Biotherapeutics by 133.5% in the second quarter. Bank of America Corp DE now owns 1,202,513 shares of the company’s stock worth $16,859,000 after acquiring an additional 687,562 shares during the period. Zevenbergen Capital Investments LLC purchased a new position in Arcutis Biotherapeutics in the fourth quarter valued at about $12,140,000. Finally, Qube Research & Technologies Ltd grew its position in shares of Arcutis Biotherapeutics by 200.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 577,493 shares of the company’s stock valued at $8,096,000 after acquiring an additional 385,274 shares during the period.

Analyst Ratings Changes

Several brokerages have recently issued reports on ARQT. Mizuho decreased their price target on shares of Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating for the company in a research note on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Friday, March 27th. HC Wainwright increased their price objective on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $36.00 target price on shares of Arcutis Biotherapeutics in a research report on Thursday, May 7th. Finally, TD Cowen boosted their target price on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.00.

Read Our Latest Stock Report on ARQT

Insider Buying and Selling

In other Arcutis Biotherapeutics news, Director Howard G. Welgus sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $23.88, for a total value of $238,800.00. Following the completion of the transaction, the director owned 39,744 shares in the company, valued at $949,086.72. This trade represents a 20.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Todd Watanabe sold 37,349 shares of Arcutis Biotherapeutics stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $25.18, for a total value of $940,447.82. Following the transaction, the insider directly owned 785,957 shares of the company’s stock, valued at $19,790,397.26. The trade was a 4.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 92,831 shares of company stock valued at $2,295,499 in the last 90 days. Corporate insiders own 9.40% of the company’s stock.

Arcutis Biotherapeutics Stock Performance

Shares of ARQT stock opened at $21.24 on Tuesday. The firm’s 50 day moving average is $23.39 and its 200 day moving average is $25.78. The stock has a market capitalization of $2.66 billion, a P/E ratio of -707.76 and a beta of 1.58. Arcutis Biotherapeutics, Inc. has a 12 month low of $12.72 and a 12 month high of $31.77. The company has a current ratio of 2.68, a quick ratio of 2.46 and a debt-to-equity ratio of 0.54.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.07). Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative return on equity of 1.41%. The business had revenue of $105.40 million during the quarter, compared to analysts’ expectations of $103.68 million. On average, sell-side analysts anticipate that Arcutis Biotherapeutics, Inc. will post 0.15 earnings per share for the current year.

Arcutis Biotherapeutics Company Profile

(Free Report)

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.